2013 AACR Annual Meeting

breast cancer

Higher HER2 Expression Linked to Best Results with T-DM1 in Patients with HER2-positive Metastatic Breast Cancer

A biomarker analysis of the pivotal EMILIA trial suggests that women with metastatic HER2-positive breast cancer with tumors that have high expression of HER2 derive the most robust benefit from treat...

gynecologic cancers

Combinatorial Immunologic Approach Yields Benefit in Preliminary Study of Recurrent Ovarian Cancer

A two-step immunologic approach that includes a personalized dendritic cell vaccine for each patient followed by adoptive T-cell therapy holds promise for the treatment of recurrent ovarian cancer, ac...

hematologic malignancies

Preliminary Progress with Genetically Engineered T Cells in Treating Childhood ALL 

Two small phase I studies at separate centers demonstrated encouraging results in the treatment of children with acute lymphoblastic leukemia (ALL) using reinfused autologous genetically engineered T ...


Promising Phase II Results Continue to Support Ibrutinib in CLL  

Results from an ongoing phase II study reported at the recent Annual Meeting of the American Association for Cancer Research (AACR) demonstrate impressive activity with the use of ibrutinib in patient...

head and neck cancer

Novel Approaches to Genetic Testing and Overcoming Treatment Resistance Highlighted at AACR Meeting 

Below are brief summaries of highlights from the very full, comprehensive collection of studies presented at the American Association of Cancer Research (AACR) Annual Meeting in Washington, DC. The ab...

issues in oncology

Tobacco Use in Cancer Patients: Often Overlooked but Critical to Address 

One would hope that the importance of treatment for tobacco dependence would be well recognized as a cornerstone of standard care for cancer patients. However, a policy statement released by the Ameri...